Ensign Group Slips Into Earnings as Call Buyers Take Over

The Ensign Group reports its latest quarterly results today, and the stock arrives at the print down 3.7% on the week, a notably weaker run than the median gain of roughly 1.9% posted by its closest healthcare peers over the same period.

The most striking positioning signal comes from the options market, which has swung sharply toward calls. The put/call ratio dropped to 0.49 on Tuesday, almost 2.8 standard deviations below its 20-day average of 0.58. That is the most bullish options tilt seen in months on this name, sitting near the low end of the 52-week range. The divergence between falling share price and rising call interest is the defining tension coming into today's release. The borrow market adds little to the short-seller story: availability is extraordinarily loose at 7,375%, meaning there are roughly 73 times as many shares available to lend as are currently short. Cost to borrow has fallen 36% over the past week to just 0.20%. Short interest, at 2.4% of the free float, is low and has drifted sideways over the past month.

The analyst community is broadly constructive but not unanimously so. RBC Capital carries an Outperform with a $222 target, and UBS rates the stock Buy. Truist Securities, by contrast, has stayed at Hold through two target revisions this year, most recently lifting to $207 in late July while the stock was trading around $185. The mean target implies roughly 30% upside from Tuesday's close of $169.50. The bull case rests on Ensign's decentralised operating model, a consistent acquisition cadence, and guidance that beat consensus expectations earlier in the year. Bears point to reimbursement pressure from Medicare and Medicaid, labour costs, and an adjusted net debt to EBITDA ratio of approximately 1.77 times. Valuation has eased with the share price: the trailing PE has compressed to just over 20 times and EV/EBITDA to about 14.3 times, both roughly one full multiple point lower than 30 days ago.

On the ownership side, the picture is relatively stable. BlackRock holds just over 10% and added shares as recently as the September quarter. Baillie Gifford, with around 8.7%, is a known long-term growth holder. Insider activity over the past 90 days has been minimal in dollar terms: net sales of roughly $154,000, almost entirely small director transactions under pre-arranged trading plans, with no open-market purchases of note. That is neither a red flag nor a conviction signal.

The print today is ultimately a test of whether Ensign's acquisition-driven growth model is delivering at the margin level the current valuation requires, particularly against a backdrop where peers like PACS and EHC have gained 6% and 2% respectively on the week while ENSG has fallen. The gap between bullish options positioning and a weakening share price leaves the two sides of the trade pointing in opposite directions going into the numbers.